CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Connect® Myeloid Disease Registry

Recruiting

Conditions: Primary Myelofibrosis
Myelodysplastic Syndromes
Leukemia, Myeloid, Acute

Interventions: Drug: Luspatercept

First Posted Date: 2012-09-19

Last Posted Date: 2024-05-02

Lead Sponsor: Celgene

Target Recruit Count: 2300

Registration Number: NCT01688011

Locations: 🇺🇸
Local Institution - 1088, Cleveland, Ohio, United States
🇺🇸
Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
🇺🇸
TriHealth, Good Samaritan Hospital, Cincinnati, Ohio, United States

and more 236 locations

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: pegylated liposomal doxorubicin (PLD)
Drug: Placebo
Drug: VTX-2337

First Posted Date: 2012-08-16

Last Posted Date: 2019-09-26

Lead Sponsor: Celgene

Target Recruit Count: 297

Registration Number: NCT01666444

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Aspirus Regional Cancer Center, Wausau, Wisconsin, United States
🇺🇸
Johns Hopkins Medical Institution, Baltimore, Maryland, United States

and more 124 locations

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Ozanimod
Drug: Placebo

First Posted Date: 2012-07-23

Last Posted Date: 2021-05-19

Lead Sponsor: Celgene

Target Recruit Count: 199

Registration Number: NCT01647516

Locations: 🇸🇰
Slovak Research Center, Ilava, Slovakia
🇧🇬
University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD, Sofia, Bulgaria
🇧🇬
University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia, Sofia, Bulgaria

and more 85 locations

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma

Conditions: Multiple Myeloma

First Posted Date: 2012-07-03

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Registration Number: NCT01632826

Locations: 🇨🇦
Celgene Study Site, Saskatoon, Saskatchewan, Canada

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

Phase 2

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Ozanimod
Drug: Placebo

First Posted Date: 2012-06-26

Last Posted Date: 2021-02-11

Lead Sponsor: Celgene

Target Recruit Count: 258

Registration Number: NCT01628393

Locations: 🇧🇪
Centre Hospitalier Chretien Clinique Saint Joseph, Montegnee, Belgium
🇧🇪
Clinique Saint-Pierre, Ottignies, Belgium
🇧🇪
Cliniques Universitaires St-Luc, Brussels, Belgium

and more 55 locations

A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects

Phase 1

Completed

Conditions: Safety and Pharmacokinetics in Healthy Volunteer Subjects

Interventions: Drug: CC-223

First Posted Date: 2012-06-05

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 18

Registration Number: NCT01611467

Locations: 🇺🇸
Covance Research Unit, Inc, Madison, Wisconsin, United States

Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Myelodysplastic Syndrome (MDS)

Interventions: Drug: Azacitidine

First Posted Date: 2012-05-16

Last Posted Date: 2019-03-19

Lead Sponsor: Celgene

Target Recruit Count: 72

Registration Number: NCT01599325

Locations: 🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳
The 301 Hospital- Chinese PLA General Hospital, Beijing, China
🇨🇳
The Third Hospital of Peking University, Beijing, China

and more 8 locations

Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2012-05-08

Last Posted Date: 2017-09-20

Lead Sponsor: Celgene

Target Recruit Count: 194

Registration Number: NCT01593410

Locations: 🇨🇳
307 Hospital of Chinese PLA, Beijing, China
🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳
Chinese PLA General Hospital, Beijing, China

and more 9 locations

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: ACY-1215
Drug: lenalidomide
Drug: Dexamethasone

First Posted Date: 2012-04-24

Last Posted Date: 2022-02-23

Lead Sponsor: Celgene

Target Recruit Count: 38

Registration Number: NCT01583283

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 2 locations

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)

Phase 1

Completed

Conditions: Multiple Myeloma
Renal Impairment

Interventions: Drug: 2 mg Oral POM + 40 mg Oral DEX
Drug: 4 mg Oral POM + 40 mg Oral DEX

First Posted Date: 2012-04-12

Last Posted Date: 2022-11-04

Lead Sponsor: Celgene

Target Recruit Count: 25

Registration Number: NCT01575925

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Ingalls Cancer Research Center, Harvey, Illinois, United States
🇨🇦
L'Hotel Dieu de Quebec, Quebec, Canada

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy